BRPI0821739B8 - sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga - Google Patents

sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga

Info

Publication number
BRPI0821739B8
BRPI0821739B8 BRPI0821739A BRPI0821739A BRPI0821739B8 BR PI0821739 B8 BRPI0821739 B8 BR PI0821739B8 BR PI0821739 A BRPI0821739 A BR PI0821739A BR PI0821739 A BRPI0821739 A BR PI0821739A BR PI0821739 B8 BRPI0821739 B8 BR PI0821739B8
Authority
BR
Brazil
Prior art keywords
delivery system
drug delivery
methyl ester
pharmaceutical composition
dds
Prior art date
Application number
BRPI0821739A
Other languages
English (en)
Portuguese (pt)
Inventor
Lokot Igor
Aleksov Julian
Original Assignee
Ardenia Investments Ltd
Oasmia Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardenia Investments Ltd, Oasmia Pharmaceutical Ab filed Critical Ardenia Investments Ltd
Publication of BRPI0821739A2 publication Critical patent/BRPI0821739A2/pt
Publication of BRPI0821739B1 publication Critical patent/BRPI0821739B1/pt
Publication of BRPI0821739B8 publication Critical patent/BRPI0821739B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0821739A 2007-12-19 2008-12-18 sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga BRPI0821739B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SEPCT/SE2007/001128 2007-12-19
PCT/SE2007/001128 WO2009078755A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
PCT/SE2008/051517 WO2009078804A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Publications (3)

Publication Number Publication Date
BRPI0821739A2 BRPI0821739A2 (pt) 2015-06-16
BRPI0821739B1 BRPI0821739B1 (pt) 2021-03-02
BRPI0821739B8 true BRPI0821739B8 (pt) 2021-05-25

Family

ID=40795733

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821739A BRPI0821739B8 (pt) 2007-12-19 2008-12-18 sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica e método de preparação de sistema de liberação de droga

Country Status (23)

Country Link
US (1) US8324274B2 (enExample)
EP (1) EP2231193B1 (enExample)
JP (1) JP5466174B2 (enExample)
KR (1) KR101616135B1 (enExample)
CN (1) CN101945671B (enExample)
AU (1) AU2008339101B2 (enExample)
BR (1) BRPI0821739B8 (enExample)
CA (1) CA2709268C (enExample)
CY (1) CY1121145T1 (enExample)
DK (1) DK2231193T3 (enExample)
EA (1) EA018559B1 (enExample)
ES (1) ES2689509T3 (enExample)
HR (1) HRP20181517T1 (enExample)
HU (1) HUE039695T2 (enExample)
LT (1) LT2231193T (enExample)
MX (1) MX2010006906A (enExample)
MY (1) MY150820A (enExample)
NZ (1) NZ586858A (enExample)
PL (1) PL2231193T3 (enExample)
PT (1) PT2231193T (enExample)
SI (1) SI2231193T1 (enExample)
WO (2) WO2009078755A1 (enExample)
ZA (1) ZA201004992B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
CN112321465B (zh) 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
CN115212220A (zh) * 2021-04-16 2022-10-21 上海现代药物制剂工程研究中心有限公司 一种药物递送系统及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
HK1041889B (zh) * 1999-03-11 2005-03-18 阿登尼亚投资有限公司 治疗癌症的新化合物
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
SE0202311D0 (sv) * 2002-07-23 2002-07-23 Ardenia Investments Ltd Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US20050196343A1 (en) * 2004-02-27 2005-09-08 Molecular Therapeutics, Inc. Degradable nanoparticles
US8945629B2 (en) * 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Also Published As

Publication number Publication date
LT2231193T (lt) 2018-11-12
WO2009078804A1 (en) 2009-06-25
AU2008339101B2 (en) 2015-08-06
EA018559B1 (ru) 2013-08-30
CA2709268C (en) 2016-02-09
JP2011507840A (ja) 2011-03-10
PT2231193T (pt) 2018-11-02
EP2231193A1 (en) 2010-09-29
ES2689509T3 (es) 2018-11-14
JP5466174B2 (ja) 2014-04-09
BRPI0821739B1 (pt) 2021-03-02
EP2231193A4 (en) 2014-12-03
CA2709268A1 (en) 2009-06-25
US8324274B2 (en) 2012-12-04
DK2231193T3 (en) 2018-10-22
AU2008339101A1 (en) 2009-06-25
ZA201004992B (en) 2011-03-30
EP2231193B1 (en) 2018-07-18
BRPI0821739A2 (pt) 2015-06-16
CY1121145T1 (el) 2020-05-29
EA201070626A1 (ru) 2010-12-30
HUE039695T2 (hu) 2019-01-28
MX2010006906A (es) 2010-11-10
KR20100099290A (ko) 2010-09-10
NZ586858A (en) 2012-06-29
US20110236472A1 (en) 2011-09-29
PL2231193T3 (pl) 2019-01-31
CN101945671B (zh) 2012-08-22
KR101616135B1 (ko) 2016-04-27
HRP20181517T1 (hr) 2018-11-30
SI2231193T1 (sl) 2018-12-31
WO2009078755A1 (en) 2009-06-25
CN101945671A (zh) 2011-01-12
MY150820A (en) 2014-02-28

Similar Documents

Publication Publication Date Title
Illum Nasal drug delivery—Recent developments and future prospects
Jacob et al. An updated overview of the emerging role of patch and film-based buccal delivery systems
Ghori et al. Nasal drug delivery systems: an overview
Varghese et al. Cubosomes in cancer drug delivery: A review
Nunes et al. Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimer’s drugs
Chang et al. Hyaluronan-loaded liposomal dexamethasone–diclofenac nanoparticles for local osteoarthritis treatment
Neupane et al. Transdermal delivery of chemotherapeutics: Strategies, requirements, and opportunities
Liu et al. Design of amphotericin B oral formulation for antifungal therapy
TWI732773B (zh) 用於奈米顆粒冷凍乾燥形式的組成物及方法
Bathara et al. Exploring the promising potential of high permeation vesicle-mediated localized transdermal delivery of docetaxel in breast cancer to overcome the limitations of systemic chemotherapy
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
JP7568185B2 (ja) アミノ酸ベースの栄養素の使用及びそれを含む医薬組成物
CY1121145T1 (el) Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας
CN104546691A (zh) 一种关节腔注射用温敏原位凝胶制剂组合物及其制备方法
Andrianov et al. Microneedles with intrinsic immunoadjuvant properties: microfabrication, protein stability, and modulated release
Bei et al. Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption
CN106943379A (zh) 一种藤黄酸白蛋白纳米粒及其制备方法
Wang et al. Ceramide lipid-based nanosuspension for enhanced delivery of docetaxel with synergistic antitumor efficiency
Velagacherla et al. Advances and challenges in nintedanib drug delivery
BRPI0821741B8 (pt) sistema de liberação de droga para administração de uma substância anfifílica catiônica farmaceuticamente ativa compreendendo nanopartículas, composição farmacêutica, método de preparação de composição farmacêutica e seu uso
CN104546741A (zh) 一种2-甲氧基雌二醇白蛋白纳米冻干剂制备方法及其应用
Aati et al. Intratracheal administration of itraconazole-loaded hyaluronated glycerosomes as a promising nanoplatform for the treatment of lung cancer: formulation, physiochemical, and in vivo distribution
Jon et al. Recent advances in donepezil delivery systems via the nose-to-brain pathway
O’Neill et al. Edaravone for the treatment of motor neurone disease: a critical review of approved and alternative formulations against a proposed quality target product profile
KR20110114914A (ko) 약물 전달을 위한 ｐＨ-민감성 나노입자 및 이의 제조방법

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/51 (2006.01), A61K 9/00 (2006.01), A61K 9/1

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25C Requirement related to requested transfer of rights

Owner name: ARDENIA INVESTMENTS, LTD. (GB)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870190091715 DE 13/09/2019, E NECESSARIO APRESENTAR DOCUMENTO DEVIDAMENTE NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, TRADUCAO JURAMENTADA DO MESMO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25B Requested transfer of rights rejected

Owner name: ARDENIA INVESTMENTS, LTD. (GB)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870190091715 DE 13/09/2019, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2543, DE 01/10/2019.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: OASMIA PHARMACEUTICAL AB (SE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2859 DE 21-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.